CTOs on the Move

Aptinyx

www.aptinyx.com

 
Aptinyx Inc. (formerly Naurex Inc.) is a biopharmaceutical company focused on discovery and development of transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering compounds that enhance synaptic plasticity, or strengthen the network for neural cell communication. Molecules discovered by Aptinyx achieve this through a novel mechanism that modulates NMDA receptors, resulting in drugs that are both highly effective and well tolerated. This mechanism has applicability across a number of brain and nervous system disorders. Aptinyx is rapidly advancing promising drug candidates into clinical development for indications with high unmet medical ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.aptinyx.com
  • 1801 Maple Avenue Suite 4300
    Evanston, IL USA 60201
  • Phone: 847.871.0377

Executives

Name Title Contact Details

Funding

Aptinyx raised $65M on 05/10/2016
Aptinyx raised $35M on 01/14/2020

Similar Companies

Hansa Biopharma

We are dedicated to developing lifesaving and life-altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.

Cofactor Genomics

Cofactor Genomics is pioneering the use of RNA to diagnose disease.

EcoArray

EcoArray is a Gainesville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BD Biosciences - Canada

BD Biosciences - Canada is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axcella Health

Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.